Immunome reports Q3 net loss of $8.5M; cash $27.1M; COVID antibody trial on track

Immunome Inc.

2022-Q3 EPS reported -$2.45

Net loss for Q3 2022 was $8.5 million; no revenue from product sales.
R&D expenses $5.2M, G&A $3.3M; cash and equivalents $27.1M as of Sept 30.
IMM-BCP-01 Phase 1b enrollment expected by end of 2022; topline data early 2023.
Oncology pipeline advancing; IND for IMM-ONC-01 planned by mid-2023.
Preclinical data on anti-EPN1 antibody IMM20059 at SITC showed combo effect with atezolizumab.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunome Inc. reported third quarter ended September 30, 2022 results: net income $8.5 million.

Period: third quarter ended September 30, 2022
Net income: $8.5 million
Result: reported results

Exact text from the filing

Net loss: Net loss for the three months ended 2022 was $8.5 million.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-117891

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.